Lupus Clinical Trials in Bethesda, Maryland
9 recruitingBethesda, Maryland
Showing 1–9 of 9 trials
Recruiting
Phase 1
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
Systemic Lupus Erythematosus (SLE)Primary Ovarian Insufficiency (Poi)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)100 enrolled1 locationNCT05567198
Recruiting
Phase 3
An Efficacy and Safety Study of Intravenous Anifrolumab to Treat Systemic Lupus Erythematosus in Pediatric Participants
Systemic Lupus Erythematosus
AstraZeneca100 enrolled99 locationsNCT05835310
Recruiting
Phase 1
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Malignant Solid NeoplasmHematopoietic and Lymphoid Cell NeoplasmRheumatoid Arthritis+11 more
National Cancer Institute (NCI)300 enrolled52 locationsNCT03816345
Recruiting
Patient-Centered Assessment of Symptoms and Outcomes
Myalgic Encephalomyelitis/Chronic Fatigue SyndromeCancerFatigue+5 more
National Center for Complementary and Integrative Health (NCCIH)692 enrolled1 locationNCT03952624
Recruiting
Phase 1Phase 2
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
Lupus Erythematosus, Systemic
AstraZeneca150 enrolled18 locationsNCT06897930
Recruiting
Phase 1Phase 2
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
National Heart, Lung, and Blood Institute (NHLBI)78 enrolled1 locationNCT06032923
Recruiting
Study of Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)2,000 enrolled1 locationNCT00001372
Recruiting
Phase 2
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
Cardiovascular DiseaseSystemic Lupus ErythematosusPremature Atherosclerosis
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)45 enrolled1 locationNCT05440422